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ABSTRACT
The protist parasite Trypanosoma brucei causes Hu-
man African trypanosomiasis (HAT), which threat-
ens millions of people in sub-Saharan Africa. With-
out treatment the infection is almost always lethal.
Current drugs for HAT are difficult to administer
and have severe side effects. Together with in-
creasing drug resistance this results in urgent need
for new treatments. T. brucei and other trypanoso-
matid pathogens require a distinct form of post-
transcriptional mRNA modification for mitochondrial
gene expression. A multi-protein complex called the
editosome cleaves mitochondrial mRNA, inserts or
deletes uridine nucleotides at specific positions and
re-ligates the mRNA. RNA editing ligase 1 (REL1) is
essential for the re-ligation step and has no close ho-
molog in the mammalian host, making it a promising
target for drug discovery. However, traditional assays
for RELs use radioactive substrates coupled with
gel analysis and are not suitable for high-throughput
screening of compound libraries. Here we describe
a fluorescence-based REL activity assay. This as-
say is compatible with a 384-well microplate format
and sensitive, satisfies statistical criteria for high-
throughput methods and is readily adaptable for
other polynucleotide ligases. We validated the as-
say by determining kinetic properties of REL1 and
by identifying REL1 inhibitors in a library of small,
pharmacologically active compounds.
INTRODUCTION
Human African trypanosomiasis (HAT), also known as
sleeping sickness, currently affects an estimated 30 000–
50 000 people and threatens millions more (1,2). Despite
a decreasing number of new infections over the last years,
HAT still has a major impact on health and economy of
sub-Saharan Africa. A similar decline in cases in the 1960s
was followed by re-emergence due to a collapse in surveil-
lance and control activities (3). Additionally to the direct
threat to human health, Trypanosoma spp. have a heavy im-
pact on local economies by infecting livestock like cattle or
pigs. The occurrence of resistant strains in humans has been
reported but their distribution and frequency are unclear
(4). Together, these problems illustrate the urgent need for
new medication. HAT itself progresses in two stages, with
the parasite Trypanosoma brucei proliferating in the host’s
blood and lymph during the first phase, making the para-
sites relatively accessible for drugs. However, phase I usually
only shows unspecific symptoms like headache or fever and,
if untreated, the disease progresses to phase II. Here the par-
asite enters the central nervous system (3,5). This results in
various symptoms like coordination disabilities, confusion
and disturbances in sleep cycle which gave rise to the com-
mon name sleeping sickness. Left untreated HAT is almost
always fatal (6).
Trypanosoma brucei is an extracellular parasite from the
order Kinetoplastida, infecting humans as well as many
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mammals (7,8). One of the most remarkable characteris-
tics of kinetoplastids is the unusual organization of their
mitochondrial genome, the eponymous kinetoplast (9). Mi-
tochondrial proteins are encoded by a few dozen presum-
ably identical maxicircles of ∼23 kbp. In addition, the kine-
toplast also contains thousands of minicircles, each∼1 kbp
in size, encoding so called guide RNAs (gRNAs). These 50–
60 nt transcripts are essential for the expression of mito-
chondrial genes by RNA editing, directing the process by
virtue of their complementarity to fully edited mRNA (10).
Three distinct protein complexes of ∼20S, called core edi-
tosomes (or RNA editing core complexes), modify the pre-
mRNA by insertion or deletion of uridine-nucleotides (11–
14). However, auxiliary complexes are required for gRNA
processing and binding, and the editing process is integrated
into otherRNAprocessingmechanism, resulting in a highly
complex network of interactions (14,15). A single gRNA
can code for several insertions or deletions, but in most
cases editing involves sequential action of several overlap-
ping gRNAs. During editing the pre-mRNA is cut by an
endonuclease, uridine nucleosides are inserted by a terminal
uridylyl transferase (TUTase) or removed by an ExoUase,
and finally the edited mRNA strand is re-ligated by an
RNA ligase. Investigation of function and composition of
the editosomes has shown that they contain two different
trimeric subcomplexes. The first subcomplex contains struc-
tural protein KREPA2 (a.k.a. MP63), ExoUase REX2 and
RNA editing ligase 1 (REL1), the second subcomplex con-
tains structural protein KREPA1 (a.k.a. MP81), TUTase
RET2 and RNA editing ligase 2 (REL2) (13,16). The struc-
tural proteins directly interact with the enzymes and bind
them to the complex (17). While REL1 function is essential
for T. brucei survival, no negative effect has been observed
after REL2 RNAi-mediated knockdown (18–21), and the
precise functions of the two RELs in uridine insertion and
deletion editing remain to be clarified (14,21,22).
The RELs belong to the superfamily of polynucleotide
ligases which also includes DNA ligases and other RNA
ligases. This relationship is strongly supported by se-
quence comparison and structural investigations (23,24).
All polynucleotide ligases share five conservedmotifs (I, III,
IIIa, IV, V) in their catalytic domain which form the active
site and binding pocket for the cofactor adenosine triphos-
phate (ATP) or NAD+ (25). Members of this family employ
a three-step reactionmechanism. The first step is adenylyla-
tion of a 100% conserved lysine residue by use of the ATP or
NAD+ in the binding pocket. The second step is the transfer
of AMP onto the 5′ end of the donor (3′) substrate RNA or
DNA to yield a high-energy 5′-5′ pyrophosphate intermedi-
ate. In the third step the ligation of donor and acceptor (5′)
RNA or DNA takes place and AMP is released.
The essential nature of REL1, the absence of a close
homolog in the host and the availability of a high reso-
lution crystal structure of its N-terminal catalytic domain
(26) make it a very interesting target for drug development
(18). As an important step toward this goal we have now
developed a novel activity assay for REL1 that uses flu-
orophore labeled substrate RNA and is compatible with
high-throughput screening (HTS) methods for the identifi-
cation of smallmolecule inhibitors. Traditional REL1 activ-
ity assays utilize the incorporation of radioactively labeled
ATP into the ligase or the ligation of pre-cleaved radioac-
tively labeled RNA; both assays require gel electrophoresis
(27). This makes these assays relatively complicated, expen-
sive, time consuming and not amenable for high-throughput
methods. HTS-compatible, fluorescence based assays have
been described for DNA ligases (28–31) and for full-round
trypanosomeRNAediting (32,33), but not forRNA ligases.
To test the potential of our assay we used it to screen the
Library Of Pharmaceutically Active Compounds (LOPAC,
Sigma-Aldrich) for REL1 inhibitors. We confirmed activity
of five of the top six hits in individual assays and assessed
the potential binding mode of one confirmed hit, the anti-
trypanosomatid drug suramin, by modeling the interaction
with REL1 and applying molecular dynamics simulations.
MATERIALS AND METHODS
Protein production and purification
Trypanosoma brucei REL1 (systematic TriTrypDB ID
Tb927.9.4360; www.tritrypdb.org) was produced recombi-
nantly in Escherichia coli BL21 (DE3) cells. The REL1 ex-
pression construct, a generous gift fromWimHol, Junpeng
Deng and Meiting Wu (University of Washington, Seat-
tle), was generated as follows. The sequence encodingREL1
amino acids 51–469 (corresponding to the mature polypep-
tide without the mitochondrial targeting signal) was cloned
into pET-21d (Novagen). Additionally the sequence for a
6xHis-tag followed by a linker and amino acids 56–176 from
KREPA2 (systematic TriTrypDB ID Tb927.10.8210), cor-
responding to the region directly interacting with REL1
(17), was cloned into the same vector downstream of the
REL1 coding sequence. Competent BL21 (DE3) cells were
transformed with this polycistronic construct and grown at
37◦C to an OD of ∼0.4. Expression was induced with 0.1–
0.5 mM IPTG and performed at 20◦C for 20 h. Cells were
harvested by centrifugation. The cell pellet was resuspended
in 20 mM Tris/HCl pH 8.0, 500 mMNaCl, 10% (v/v) glyc-
erol, 2 mM DTT, 0.1 mM PMSF and 1 mM benzamidine,
supplied with Roche EDTA-free protease inhibitor. Cells
were lysed with a TS Series Benchtop cell disruptor (Con-
stant Systems Ltd.) and the lysate centrifuged at 50 000 g
for 1 h. The supernatant was passed through a 0.2 m fil-
ter and applied to a HiTrap FF IMAC (GE Healthcare)
charged with Ni2+. After a wash step with 40 mM imida-
zole, protein was eluted with a linear 40–500 mM imida-
zole gradient. Elution fractions were analyzed by sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) and suitable fractions were pooled. Protein was then
concentrated to 10 mg/ml, flash frozen in liquid nitrogen
and stored at -80◦C.
Assay development and optimization
Labeled and unlabeled synthetic RNA oligonucleotides
were produced by IBA GmbH Go¨ttingen, Germany, us-
ing phosphoramidites from Thermo Fisher Scientific; all
oligonucleotides were purified by reversed phase HPLC.
RNA for fluorophore labeling was synthesized with
amino modifier C6-U at the respective position, and N-
hydroxysuccinimide (NHS) esters of the dyes, which form
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an amide bond with the reactive amine, were used for la-
beling. Dye-labeled oligonucleotides were purified with an
additional HPLC step after labeling. To determine the ideal
conditions for RNA ligation and optimal FRET signal
readout, several assay variables like type of fluorophore,
temperature, buffer, pH, additives and denaturing methods
were systematically tested. Initial RNA annealing and lig-
ation conditions were as follows. Per reaction, 1 l each
of 5′-RNA (5′-AAG /U-6FAM/AU GAG ACG UAG G-
3′), 3′-RNA (5′-pAUUGGAG/U-Cy5/UAUAGp-3′) and
gRNA bridge (5′-CUA UAA CUC CAA UCC UAC GUC
UCA UAC UUp-3′) (all 10 M) were mixed with 1 l 10×
reaction buffer (250 mM KCl; 125 mM HEPES pH 7.9; 50
mMMg(OAc)2; 2.5 mMDTT; 1% (w/v) Triton X-100) and
6l H2O, incubated at 70◦C for 2min and cooled to 20◦C at
0.1◦C/s. A total of 50 ng of REL1 were mixed in a total vol-
ume of 10l with 1g BSA, 1l 200MATP and 1l 10×
reaction buffer. Enzyme and substrate mix were combined
and incubated at 27◦C for 30min. For heat denaturation, 80
l stop buffer (25 M competitor DNA oligonucleotide 5′-
AAG TAT GAG ACG TAG GAT TGG AGT TAT AG-3′;
12.5 M EDTA) was added, the sample incubated at 95◦C
for 2 min and then transferred to a 96-well plate (Greiner
Bio-One 655083). Fluorescence was measured in a BMG
Labtech FLUOstar Omega plate reader (excitation at 490
nm, detection at 670 nm).
Assay conditions for HTS in 384-well format
Substrate RNAs were annealed in the presence of 25 mM
KCl, 12.5 mMTris–HCl pH 8.0, 5 mMMg(OAc)2 and 0.25
mM DTT at a concentration of 1 M in 10-ml batches
by incubation at 70◦C for 10 min, followed by slow cool-
ing to room temperature. Annealed substrate was stored at
−80◦C. For 2400 assays, 2.4 l 100 mM ATP were added
to 12 ml pre-annealed substrate and 5 l of the mixture
dispensed into each well of a 384-well assay plate (Greiner
788075). A total of 50 nl of LOPAC (Sigma-Aldrich; 2 mM
in DMSO) or Maybridge Hitfinder (Thermo Fisher Scien-
tific; 2 mM in DMSO) compounds were added per well us-
ing a Biomek FX instrument. Recombinant REL1 was di-
luted in 10% (v/v) glycerol, 300 mM NaCl, 2 mM DTT
and 20 mM Tris–HCl pH 6.0 to a final concentration of
300 ng/l. One hundred twenty microliter REL1 solution
were added to 11.88ml ligation buffer (5mMKCl; 12.5mM
Tris–HCl pH 6.0; 1 mM Mg(OAc)2; 0.25 mM DTT, 0.2%
(w/v) Triton X-100; 0.003% (w/v) Brij 35) and 5 l of the
REL1/ligation buffer mix were added to each well to start
the reaction (15 ng/l REL1 per well). A total of 50 M
NSC-42067 served as positive control for inhibition (34).
As additional controls, each plate included reactions with-
out inhibitor and reactions without REL1. After 30 min in-
cubation at room temperature the reaction was stopped by
adding 12.5 l STOP solution (9 M urea; 20 mM EDTA).
After a minimum incubation period of 15 min plates were
read using a ratiometric wavelength read (excitation at 485
nm, detection at 665 and 535 nm). HTS was carried out at
The Scripps Research Institute, San Diego, CA, USA.
Gel electrophoresis
After ligation reaction, 20% (w/v) polyacrylamide gels were
used to separate the RNA molecules by non-denaturing
PAGE in Tris-borate-EDTA (TBE) buffer. For denaturing
PAGE, gels contained 7 M urea. Gels were analyzed using
a Typhoon FLA 7000 (GE Healthcare).
Protein docking and modeling
The first model of suramin bound simultaneously to the ac-
tive sites of two REL1 enzymes was built manually using
Maestro from Schro¨dinger (35). Initially, half of suramin,
which is symmetrical, was modeled into the active site of
the REL1 crystal structure (26). Structural water molecules
were deleted prior to this step to allow positioning of the
ligand. The resulting complex was minimized to optimize
enzyme-ligand interactions. Subsequently, a copy wasmade
of that complex, which was then reflected in the symme-
try point of suramin. The two halves of suramin were sub-
sequently bonded. To generate subsequent models, single
bonds in suramin were rotated while the enzymes with re-
spect to the ligand were fixed; this forced a rigid body ro-
tation of the enzymes with respect to one another to find
allowed conformations where the enzymes did not clash.
To evaluate the stability of both the ligand binding mode
and the proteins adjacent to each other, molecular dynam-
ics simulations of the complexes were carried out (further
details can be found in the Supplementary Data).
RESULTS
Protein production and purification
We were unable to obtain soluble, full-length REL1 when
expressed on its own in E. coli. However, a di-cistronic
construct for co-expression of REL1 with a fragment of
KREPA2 (amino acid residues 56–176; plasmid generously
provided by Wim Hol, University of Washington), permit-
ted expression of soluble REL1. This region of KREPA2
interacts with the C-terminal domain of the ligase (17,36)
and probably supports its correct folding in E. coli. Recom-
binant protein expression in E. coli BL21 (DE3) using LB
medium resulted in an initial ratio of roughly 2:1 of insol-
uble to soluble protein (estimated from relative band in-
tensity on Coomassie-stained SDS-PAGE gels). Reducing
IPTG concentration from 0.5 mM to 0.1 mM and adding a
10min heat shock at 42◦C directly before induction resulted
in an optimized ratio of∼1:1 and an increased yield of solu-
ble REL1-KREPA256–176 protein complex. Using a 6xHis-
tag at the N-terminus of KREPA256–176 for IMAC purifi-
cation, the REL1-KREPA256–176 complex could be isolated
to >95% purity (Figure 1A).
Assay development and optimization
Synthetic substrates developed for traditional in vitro edit-
ing and ligation assays (37) were modified by internal at-
tachment of the donor (6-FAM) and acceptor fluorophore
(Cy5) of a Fo¨rster Resonance Energy Transfer (FRET) pair
to the 5′-RNA and 3′-RNA oligonucleotides, respectively.
After annealing of 5′-RNA and 3′-RNA to a complemen-
tary gRNA, close proximity of the two fluorophores in the
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Figure 1. Purification of recombinant REL1 and initial characterization of the FRET-based assay. (A) SDS-PAGE showing the purified REL151–469-
KREPA251–176 complex. REL151–469 has a size of 46.9 kDa, while 6xHis-KREPA251–176 has a size of 16.5 kDa. (B) Schematic representation of the assay
principle. A nicked RNA duplex consisting of guide RNA (gRNA), 5′-RNA with donor fluorophore and 3′-RNA with acceptor fluorophore serves as
substrate. After incubation with REL1, ligated RNA is detected by denaturation-resistant FRET between the two fluorophores. (C) The FRET signal
is dependent on ATP and REL1. The assay was carried out as described in ‘Materials and Methods’ section under ‘Initial RNA annealing and ligation
conditions’, except 100 ng REL1 and the concentrations of ATP indicated were used. Means and standard deviations for three independent experiments
are shown. (D) The FRET signal is dependent on gRNA. The assay was carried out as described in ‘Materials and Methods’ section under ‘Initial RNA
annealing and ligation conditions’, except 200 ng REL1 were used, gRNA was added or omitted as indicated and samples were or were not denatured at
96◦C before reading, as indicated. Means and standard deviations for five (+gRNA) or three (−gRNA) replicates are shown.
dsRNA results in FRET. After sealing of the nick (e.g.
by active REL1), the FRET signal will be unaffected by
dsRNA denaturation (Figure 1B). Preventing sealing of the
nick (e.g. by inhibition of REL1 activity) will result in loss
of the FRET signal after dsRNA denaturation. As shown
in Figure 1C and D, the FRET signal shows the expected
dependency on REL1, ATP and gRNA. Reactions without
exogenous ATP gave a slightly higher signal than reactions
without REL1 (Figure 1C). This has previously been ob-
served for editosomes purified from T. brucei (37,38) as well
as for recombinant phage RNA ligase T4Rnl2 (24,39)––the
closest known homolog of the RELs (26)––and is due to
some ligase being pre-adenylylated when isolated from cells.
The dependence on gRNA is consistent with earlier re-
ports that unbridged RNA molecules are poor substrates
for the RELs (37,38). Efficient denaturation was achieved
by incubating the samples at 96◦C in the presence of 200-
fold excess of a DNA oligo that is complimentary to the
gRNA. This reduced the signal of unligated RNAs to that
of control reactions without both gRNA andREL1 (Figure
1D, compare heat denatured ‘−REL, +gRNA’ to ‘−REL1,
−gRNA’). Gel electrophoresis confirmed generation of the
expected products after annealing of the synthetic RNA
substrates and incubation with REL1 (Supplementary Fig-
ures S1 and S2). For both fluorophores, two alternative at-
tachment sites were also tested (6-FAM attached to the first
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uridylyl on the 5′-RNA andCy5 attached to the third uridy-
lyl on the 3′-RNA, compare to Figure 1B; the attachment
chemistry limited the possible attachment sites to uridy-
lyls). The RNA molecules were tested in all four combina-
tions. The combination shown in Figure 1B gave an at least
three-fold better signal-to-baseline ratio (S:B; baseline de-
fined as reaction without ligase) than the other combina-
tions (data not shown) and was used for further optimiza-
tions. Replacing 6-FAM with Cy3 as donor resulted in an
approximately five-fold drop in S:B (Supplementary Figure
S3A and B). Consequently, subsequent optimizations were
performed using the 6-FAM/Cy5 combination (excitation
at 490 nm, detection at 670 nm). Note that the binding ki-
netics for unlabeled or fluorophore-labeled RNA substrates
to REL1 were not determined. It is possible that the fluo-
rophores affect binding to REL1, for example by steric hin-
drance, and such effects may in part be responsible for the
differences in S:B ratios observed for the various combina-
tions tested above.
To determine suitable temperatures for the ligation reac-
tion a range from 12.0–40.5◦C was tested. As shown in Fig-
ure 2A, 22◦C and 27◦C resulted in the strongest FRET sig-
nals, with higher temperatures possibly decreasing enzyme
and/or substrate stability. Testing a pH range of HEPES
and Tris–HCl buffers for the ligation reaction showed that
Tris–HCl pH 6.0 gave the best S:B ratio (Supplementary
Figure S3C, Figure 2B). Similar experiments using differ-
ent buffers and pH values for the RNA annealing reaction
showed that Tris–HCl buffer with pH 8.0 resulted in the best
S:B ratio (Figure 2C; note that the resulting pH in the liga-
tion reaction is 7.0). Several additional buffer components
were tested to enhance ligation efficiency. Of the Mg2+ and
K+ concentrations tested, 50 mMMg2+ and 250 mMK+ in
the 10× annealing buffer and 10 mMMg2+ and 50 mMK+
in the 10× ligation buffer were optimal (data not shown).
The presence of six cysteines in the REL1–KREPA256–176
complex, four in REL1 and two in KREPA256–176, makes
formation of disulphide bonds a possible way of protein
denaturation. Accordingly, 2.5 mM DTT was used during
purification and in all activity assays. However, since 2-
mercaptoethanol (2-ME) has a longer half-life than DTT
(40) it was tested as an alternative reducing agent. Initial ex-
periments with pre-ligated FRET substrate indicated that
2-ME had no negative effect on the FRET signal (data
not shown). However, independently of buffer or pH, 0.2%
(v/v) 2-ME resulted in a much lower S:B ratio after the lig-
ation reaction compared to 2.5 mM DTT (Figure 2D). It
is possible that the smaller 2-ME can enter the REL1 ATP
binding pocket and modify a cysteine involved in forming
the active center (26), thereby altering the affinity and ac-
tivity of REL1. The larger DTT would not be able to enter
the binding pocket.
The presence of detergents in the assay proved bene-
ficial. A final concentration of 0.1% (w/v) Triton X-100
improved the S:B ratio and resulted in faster reaction ki-
netics (Figure 3A). Titration of Triton X-100 and Brij-35
showed that a combination of 0.1% (w/v) Triton X-100 and
0.003% (w/v) Brij-35 gave the best results (data not shown).
The small amount of detergents might stabilize REL1 or
KREPA256–176 by increasing protein solubility, reduce pro-
tein binding to the well surface and/or help release ligated
RNA product from REL1.
In our assay, distinguishing ligated from un-ligated sub-
strate with good sensitivity and specificity depends upon a
complete separation of the fluorophore-labeled RNAs from
the gRNA bridge at the end of the reaction. Heat denatu-
ration at 96◦C in the presence of excess competitor DNA
(complementary to gRNA) proved efficient in small scale
experiments (see Figure 1D). However, this method is not
ideal for anHTS setting. Therefore, urea concentrations be-
tween 1 M and 8 M were tested as a method for efficient
denaturation at room temperature. Concentrations of 4 M
urea or higher denatured RNA duplexes as effectively as in-
cubation at 96◦C (Figure 3B). The assay was not affected
by the presence of up to 5% (v/v) DMSO (Figure 3C), an
important condition for HTSwhere compounds are usually
available in this solvent. Only concentrations ≥ 10% (v/v)
DMSO resulted in a noticeable decrease of the FRET sig-
nal.
Characterization of REL1 reaction kinetics using the FRET
assay
Using the optimized conditions we next measured product
formation over time and over a range of REL1 concen-
trations (Figure 4A). As expected, product formation in-
creased with higher protein concentration as well as longer
incubation times. For 66 nM REL1, the maximum signal
was reached after 20 min. Calibration with a double 6-
FAM/Cy5-labeled control oligonucleotide determined that
the maximum signal corresponded to ligation of ∼95%
of substrate (Supplementary Figure S3D). Reactions with
lower REL1 concentrations did not reach the same max-
imum. Adding fresh ATP restarted the reaction (Supple-
mentary Figure S3E), suggesting that this observation was
not simply a consequence of deteriorating activity of the en-
zyme. The biochemical basis for this observation remains
to be investigated. Testing product formation under the as-
sumption of Michaelis–Menten kinetics using a range of
ATP concentrations and initial velocity conditions (up to
5 min) established Km, Vmax and kcat values for the co-
substrate ATP of 0.76 ± 0.27 M, 42.0 ± 4.0 nM/min and
0.54± 0.04 min−1, respectively (Figure 4B). The specific ac-
tivity of the REL1 preparation under these reaction condi-
tions was therefore 16.8 nmol min−1 mg−1 (50 ng of protein
was used per assay volume of 20 l); this value was similar
for other preparations. We caution that the kinetic parame-
ters were calculated under the assumption that 100% of the
enzyme in the preparationwas active. The actual percentage
of active protein has not been determined.
Pilot HTS and identification of REL1 inhibitors
To validate the suitability of the FRET-based REL1 activ-
ity assay forHTS, the assay conditions were adapted to 384-
well format to facilitate a pilot screen. An ATP concentra-
tion of 10 M was chosen as a compromise between sensi-
tivity to inhibition and robust S:B ratio. As positive control
for inhibition we usedNational Cancer Institute compound
NSC42067, which had previously been identified in a virtual
screen and experimentally confirmed as a REL1 inhibitor
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Figure 2. Optimization of assay conditions (I). Optimization of (A) incubation temperature, (B) pH of ligation buffer, (C) pH of annealing buffer. (D)
Assay performance with dithiothreitol (DTT) versus -mercaptoethanol (2-ME) as reducing agent. For (B), (C) and (D), parallel assays without REL1
were carried out as controls. Except for the parameters tested, all experiments were carried out as described in ‘Materials and Methods’ section under
‘Initial RNA annealing and ligation conditions’, and means and standard deviations for three replicates are shown.
that interferes with the first enzymatic step, adenylylation
(34). Using the HTS assay conditions an IC50 of 1.4 M
was determined for NSC42067 (Figure 4C; see also Sup-
plementary Figure S4). Screening the LOPAC 1280 library
(single shot assays at 10 M final concentration; four 384-
well plates, including controls) resulted in a mean Z’ score
of 0.74 and a mean S:B of 2.3, confirming suitability for
HTS (41). Applying the standard hit cut-off of three stan-
dard deviations from control samples resulted in the iden-
tification of 30 initial ‘hits’ (2.4% hit rate). Eight of these
were not reproducible, resulting in a final hit list of 22 com-
pounds (Table 1). Six of the seven compounds that showed
the strongest inhibition in the single-shot screen (Supple-
mentary Figure S5) were analyzed by dose response curves
to determine IC50 values. The compounds myricetin, tyr-
phostin AG 537, suramin, NF 023 hydrate and aurothioglu-
cose could be confirmed as inhibitors with IC50 values in the
low M range, while the initial hit methyl-3,4-dephostatin
showed no significant inhibition up to 50 M concentra-
tion (Figure 5 and Table 1). A second pilot screen against
theMaybridge library with a slightly altered liquid handling
protocol (pre-dispensing 25 l of enzyme dilution to each
of the first two well of the plate) resulted in improved HTS
statistics of an average Z’ of 0.88 and an S:B of 3.6 (Supple-
mentary Figure S6). The standard cut-off of three standard
deviations from control samples resulted in a 3.3% hit rate.
An additional reading before stopping the reaction allowed
elimination of compounds interferingwith the FRET signal
and reduced the hit rate to <1%.
Modeling suramin into the REL1 active site
Suramin’s relatively high potency combined with its large
size and symmetric character suggested that it might be
able to bind two instances of REL1 simultaneously. In-
deed, simultaneous binding of this compound to two target
molecules has been shown for Leishmania mexicana pyru-
vate kinase (LmPYK) (42). Therefore we explored whether
models of suramin binding in the ATP binding pocket of
two REL1 enzymes could be built without the two en-
zymes clashing. To create the initial model of such a com-
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Table 1. Hits from the pilot screen against the LOPAC library
Name CAS No. EC No.
PubChem
SID
Molecular
weight
Inhibition
at 10 M1
IC50
(M)2
Myricetin 529-44-2 208-463-2 24278566 318.24 100% 1.78
Methyl-3,4-dephostatin n/a n/a 24278575 168.15 97% > 50
Tyrphostin AG 537 n/a n/a 24278741 448.43 93% 0.25
Aurothioglucose hydrate 12192-57-3 235-365-7 24724383 392.18 93% 12.14
NF 023 hydrate 104869-31-0 n/a 24278597 1162.88 79% 1.95
Iofetamine hydrochloride 95896-48-3 n/a 24277716 339.64 70% n/d
Suramin sodium salt 129-46-4 204-949-3 24277738 1429.17 66% 2.94
-Lapachone 4707-32-8 n/a 24278512 242.27 48% n/d
Cefsulodin sodium salt hydrate 52152-93-9 257-692-4 24278340 554.53 46% n/d
L-Canavanine 543-38-4 n/a 24892427 176.17 46% n/d
R-(–)-Desmethyldeprenyl hydrochloride 115586-38-4 n/a 24278383 209.72 38% n/d
cDPCP 106343-54-8 n/a n/a 379.14 30% n/d
ZM 39923 hydrochloride n/a n/a 24278044 367.91 26% n/d
Auranofin n/a 251-801-9 n/a 678.48 24% n/d
8-(p-Sulfophenyl)theophylline hydrate 80206-91-3 n/a 24277683 336.32 23% n/d
MNS 1485-00-3 n/a n/a 193.16 22% n/d
2-(Methylthio)adenosine 5′-diphosphate trisodium salt hydrate 475193-31-8 n/a 24278816 539.24 22% n/d
Cephalosporin C zinc salt 59143-60-1 261-624-9 24278307 478.79 21% n/d
2-Chloroadenosine triphosphate tetrasodium hydrate n/a n/a 24277700 629.55 18% n/d
MDL 105,519 161230-88-2 n/a 24277992 376.19 18% n/d
Morin hydrate 654055-01-3 207-542-9 24278552 302.24 17% n/d
cis-Diammineplatinum(II) dichloride 15663-27-1 239-733-8 24278632 300.05 14% n/d
1As suggested by HTS; n/a, not available; n/d, not determined.
2Note that the IC50 values measured will be influenced by the percentage of active protein in the preparation, which in this case is not known.
plex we took advantage of the symmetry in suramin and
first modeled binding of the one half to a single REL1 en-
zyme using the crystal structure with ATP bound (26). Half
of suramin was placed in the active site of REL1 overlay-
ing the naphthalene moiety of suramin with that of ATP
as best possible––given the bulky sulfonate groups––while
avoiding steric clashes. The complex was then duplicated
and reflected in the symmetry point of suramin shown in
Figure 6A. The binding mode of suramin is very similar
to other sulfonated naphthalene inhibitors, V2–V4, that we
have previously discovered (34) and the naphthalene ring’s
position is very similar to that of the native ATP substrate,
also stacking with Phe209 (Figure 6B; see Supplementary
Data for further details of the binding mode). Differences
are likely due to suramin containing three bulky sulfonate
groups while the other naphthalenes contained only one or
two of these. Exploring different orientations of the two en-
zyme molecules by rigid-body rotation we found three ad-
ditional models, during the rotation where the enzymes did
not clash. To gauge whether the four models were stable,
we subjected each of them to 100 ns of molecular dynamics
(MD) simulations. The enzymes are independently very sta-
ble over the course of the simulations (Supplementary Fig-
ure S7), the protein–ligand interactions are stable, and the
water phase between the two enzymes is persistent through-
out each of the simulations. This latter part suggests that
the two enzymes do not collapse on each other as a result
of suramin binding, which is in part perhaps because the
length of suramin prevents the two proteins from clashing.
The salt-bridge between Glu60 and Arg111, which was pre-
viously reported to be dynamic during simulations (34,43),
shows similar behavior here; the interaction is broken and
intermittently formed during the simulation of some of the
models, in other models it is more stable, perhaps attributed
to Glu60’s interacting with an amine group of suramin. The
models suggest that suramin binding to two proteins is a
likely outcome and contributes to its relatively high potency.
The binding mode we modeled for suramin is also likely for
NF 023 hydrate, since these molecules are very similar, with
NF 023 hydrate having a shorter linker in the middle, allow-
ing the two enzymes to come significantly closer together.
DISCUSSION
The key editing enzyme REL1 has been validated as an es-
sential enzyme in the disease-causing bloodstream form of
T. brucei (18), but lack of a specific, HTS compatible ac-
tivity assay has hampered development of REL1 as a tar-
get for novel therapies. We have now developed a novel
FRET-based assay for REL1 that combines ease of use with
highly reliable and reproducible results, thus demonstrating
its suitability for HTS. Together with available HTS assays
that can monitor a complete cycle of editing in vitro (32,33),
this assay makes the unique RNA editing process in try-
panosomatid parasites accessible as a new target for ther-
apeutic intervention.
Several aspects of this assay have systematically been op-
timized for the use in drug discovery. For example, the use of
urea instead of heat for denaturation reduces handling time
and eliminates the need for a suitable method of heating.
One major advantage of the FRET-based assay is the di-
rect measurement of the ligated RNA product itself. Avoid-
ing indirectmeasurement through secondary products elim-
inates possible sources for errors. Using only labeled RNA
substrate enables detection of every ligated RNA strand,
dramatically increasing the S:B ratio. Given enough time
and sufficient protein concentration, almost all of the sup-
plied substrate is ligated, which increases the S:B ratio fur-
ther. Combined, these aspects result in robust screening
statistics and biologically meaningful hit identification: five
of the six hits that were selected for follow-up could be con-
firmed. The absence of sample heating, the easy execution
due to the low number of steps and components and the
low volume needed compare favorably to assays described
for DNA ligases (28–31).
Although the principal motivation for screening the
LOPAC library was to validate our assay for HTS purposes,
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Figure 3. Optimization of assay conditions (II). (A) Comparison of liga-
tion production formation over time in the presence and absence of 0.1%
(v/v) TritonX-100 (TX-100). (B) Comparison of different methods for dis-
rupting the annealed (but unligated) nicked dsRNA substrate. Denatura-
tion by 96◦C heat in the presence of 200-fold excess competitor DNA oligo
was compared to treatment with 1–8 M urea at room temperature. (C) In-
fluence of 0.2–10% (v/v) DMSO on assay performance. Except for the pa-
rameters tested, all experiments were carried out as described in ‘Materials
and Methods’ section under ‘Initial RNA annealing and ligation condi-
tions’, and means and standard deviations for three replicates are shown.
Figure 4. Kinetic characterization of REL1. (A) Product formation over
time. Substrate was incubated with different concentrations of REL1 and
urea stop buffer was added after 0–70 min. (B) Determination of Km for
ATP. The assay was carried out with varying concentrations of ATP and
50 ng REL1 in a reaction volume of 20 l. The data were fitted to the
Michaelis–Menten equation. (C) Determination of IC50 for compound
NSC42067. REL1 activity was measured in the presence of increasing con-
centrations of compound, calculated as% inhibition compared to the con-
trol, plotted and fitted to a sigmoidal curve. All experiments were carried
out under optimized conditions, and means and standard deviations for
three replicates are shown.
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Figure 5. Dose-response curves for the top six hits from the pilot screen
against the LOPAC library. Data were plotted as% inhibition compared
to controls without inhibitor and fitted to a sigmoidal curve. (A) Com-
pounds myricetin, NF023 hydrate and tyrphostin AG537. (B) Compounds
suramin, methyl-3,4-dephostatin and aurothioglucose. All experiments
were carried out under optimized conditions, and means and standard de-
viations for three replicates are shown.
the hits that were confirmed as REL1 inhibitors (suramin,
NF 023, myricetin, tyrphostin AG 537, aurothioglucose)
may prove useful. Suramin has been used for treatment of
HAT since the 1920s. Most likely it acts on several T. brucei
pathways and the exact mode of action is still not entirely
clear (42,44,45). Suramin and its analogueNF 023 have pre-
viously been identified as inhibitor of RNA editing in vitro
(32,46). One study suggested that NF 023 and suramin ‘are
either acting at a step following the endonuclease cleavage
or alternatively having global effects on the editing complex’
(32). Our confirmation of these compounds as REL1 in-
hibitors supports the first hypothesis. Interestingly, our labs
had previously identified related naphthalene-based com-
Figure 6. Proposed binding mode of suramin to REL1. (A) Predicted
binding of suramin to two REL1 enzymes simultaneously. The two en-
zymes have been colored gray and tan, respectively. Suramin is shown with
its carbon atoms colored green. Only side-chains of residues in the two
enzymes that interact with suramin are shown for clarity (carbon atoms
colored cyan). (B) Detailed view of the predicted interaction of one half
of suramin with key residues in the ATP binding pocket. Suramin, shown
with carbon atoms colored green, assumes the binding position of REL1’s
natural substrate ATP and its interactions with the enzyme. Only the side-
chains of interacting residues in the enzyme are shown for clarity (in cyan).
pounds similar to suramin and NF 023 as REL1 inhibitors
via virtual screens (34,43). However, since trypanosomes
that are not dependent on mitochondrial gene expression
show no decreased sensitivity to suramin (47), REL1 is
clearly not a relevant target of suramin in vivo. Further-
more, negatively charged compounds would require active
transport to reach suitable concentrations in the mitochon-
drial matrix, which is also negatively charged. Both suramin
and NF 023 have also been found to inhibit HCV heli-
case, another ATP-dependent nucleic acid-modifying en-
zyme (48). Crystal structures of suramin and suramin ana-
logues bound to pyruvate kinases from L. mexicana and
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Trypanosoma cruzi showed how suramin binds these pro-
teins (42). Our molecular modeling studies suggest a similar
two-to-one stoichiometry for REL1-suramin binding, and
perhaps for NF 023 as well.
Two other hits from the LOPAC screen, myricetin and
tyrphostin AG 537, share as a common feature phenyl
groups with two or one additional hydroxyl groups, respec-
tively, and this similarity could be a possible reason for
the considerable potency of both molecules toward REL1.
Nonetheless, they belong to different compound classes.
Tyrphostin AG 537, like other dimeric tyrphostins, is a po-
tent inhibitor of the oncoprotein EGF receptor tyrosine ki-
nase (49) and of dynamin I GTPase activity (50). Its rel-
atively high molecular weight makes it an unlikely candi-
date for hit-to-lead optimization. Myricetin is a naturally
occurring flavonol with strong antiradical activity and an-
tiproliferative effects on cancer lines, reportedly due to an
impairment of cell cycle progression (51). It was also iden-
tified as an inhibitor of T. brucei hexokinase 1, albeit with
only moderate potency (52). A closely related compound,
quercertin, is toxic to T. brucei gambiense in vitro with an
LD50 of 10 Mwithout affecting human hemopoietic cells
(53). These findings, combined withmyricetin’s lowmolecu-
lar weight and considerable potency toward REL1, suggest
myricetin as a possible starting point for compound opti-
mization. These examples illustrate the potential of our as-
say for finding new drug leads for HAT. The unproblematic
adaptation of the assay for 384-well format suggests feasi-
bility for a 1536-well format.
The HTS described here cannot distinguish between
competitive inhibitors of ATP binding (which would be ex-
pected to enter the ATP binding pocket), non-competitive
inhibitors that alter REL1 activity in other ways or com-
pounds that bind the RNA substrates. Compounds that in-
hibit editosome function by one of the latter two mecha-
nisms have been described (54,55). The suramin docking
studies described above and our earlier confirmation of
similar compounds as inhibitors of the adenylylation step
(34), strongly suggest that suramin and, by extension, NF
023, are indeed competitive inhibitors of ATP binding. The
mode of inhibition of the other compounds described in the
present study remains to be determined.
HAT is only one of the diseases caused by kinetoplastids
(56). Chagas disease, caused by T. cruzi is endemic to South
America and endangers tens of millions of people there
(57,58).Leishmania spp. cause leishmaniasis which results in
hundreds of thousands of deaths every year (59). All kine-
toplastids have mitochondrial RNA editing ligases highly
homologs to T. brucei REL1 (18,26). In the case of T. bru-
cei, an inhibitor of themitochondrial REL1with potency in
vivo is required to cross three membranes, which poses ad-
ditional challenges for drug development. However, a num-
ber of important existing anti-trypanosomatid drugs have
mitochondrial targets (47), a huge range of other clinically
approved drugs act directly on these organelles (60), and ap-
proaches are being developed for mitochondrial specific de-
livery (60).
Additionally to the potential for cross-trypanosomatid
drug discovery our assay also has potential as a research
tool for further investigations into REL1 function. This is
particularly relevant for T. cruzi and Leishmania, where ge-
netic tools to study gene function are less developed than in
T. brucei. In vitro and in vivo studies of REL1 biochemistry
and function have traditionally relied on assays with ra-
dioactively labeled substrates (22,26,27,61). Using our new
FRET-based assay drastically reduces the amount of pro-
tein and reagents needed as well as simplifying the process
of activity testing.
BeyondRNAediting ligases this assay has also the poten-
tial to be used with other nucleic acid ligases. The assay for-
mat can readily be adapted to study bacteriophage ligases
such as T4Rnl2 (24,62) andDNA ligases, which are pursued
as potential antimicrobial and anti-cancer targets (29,63).
Adaptation of the assay format to the latter enzymes would
also be useful to determine if REL1 inhibitors interfere with
humanDNA ligase functions and thereby estimate possible
side effects early during the drug development process.
In summary, the newRNA ligase activity assay presented
here will aid drug discovery and basic research efforts re-
garding RNA editing in trypanosomes and also promises
to assist the investigation of related nucleic acid processing
activities in other systems.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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